KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2025)

Historic Current Assets for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $714.1 million.

  • Recursion Pharmaceuticals' Current Assets rose 5060.04% to $714.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $714.1 million, marking a year-over-year increase of 5060.04%. This contributed to the annual value of $714.3 million for FY2024, which is 6302.41% up from last year.
  • Recursion Pharmaceuticals' Current Assets amounted to $714.1 million in Q3 2025, which was up 5060.04% from $587.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Current Assets ranged from a high of $714.3 million in Q4 2024 and a low of $221.8 million during Q1 2021
  • Over the past 5 years, Recursion Pharmaceuticals' median Current Assets value was $534.7 million (recorded in 2021), while the average stood at $522.8 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 17925.77% in 2022, then tumbled by 3017.73% in 2024.
  • Recursion Pharmaceuticals' Current Assets (Quarter) stood at $534.7 million in 2021, then grew by 6.56% to $569.8 million in 2022, then decreased by 23.11% to $438.1 million in 2023, then surged by 63.02% to $714.3 million in 2024, then decreased by 0.02% to $714.1 million in 2025.
  • Its last three reported values are $714.1 million in Q3 2025, $587.2 million for Q2 2025, and $584.1 million during Q1 2025.